$300B of patient health data flows every year. Patients see $0 of it.
Pharma, payers, employers, researchers, and providers buy and trade health data every day. The patient — the person whose body, time, and pain produced that data — has no seat at the table, no consent granularity, no transparency, and no economic share. Moonlitic puts the patient in the middle.
$300B+
Annual health-data market
Buyers transact today; patients are excluded.
$0
Patient share today
Zero compensation. Zero transparency.
80%
Patient share on Moonlitic
Of NET on every settled record.
11×7
Buyer × category matrix
Every query gated by consent and law.
Pilot Snapshot · illustrative · update from Chandini's deck
1,200
Patients enrolled
3
Founding council seats
4
Buyer LOIs in pipeline
2
Sponsor trials onboarding
$240K
Disbursed (test bed)
9/9
Ingestion rails wired
Patient onboard · 30 sec
Meet Sarah. Stage II breast cancer. She just signed up.
In 90 seconds, Moonlitic ingests Sarah's longitudinal record across nine independent rails — a complete picture nobody else can assemble. Watch the rails fill in.
🧑⚕️
Sarah K. Walker · 47 · Houston, TX
Stage II breast cancer · ER+/PR+/HER2− · post-lumpectomy · current AI therapy
Sarah controls what's shared. Per category. Per buyer-type. Real-time revoke.
Seven data categories. One toggle each. Sarah sees an earnings preview as she opts in. Substance Use Disorder is locked off by federal law (42 CFR Part 2) — it's never sold, regardless of consent. Genetic data is gated by GINA protections.
Demographics
Age, gender, ZIP — de-id pool
+ $40 / month preview
Clinical / EHR
Diagnoses, encounters, plans
+ $350 / month preview
Claims / EOB
837/835 derived, longitudinal
+ $180 / month preview
Imaging
DICOM studies, radiology reports
+ $220 / month preview
Genetic
GINA-gated · Insurer & Employer locked-out
+ $1,200 / month preview
Mental Health (TX §611)
State-specific re-disclosure rules
+ $90 / month preview
Substance Use Disorder
42 CFR Part 2 · never sold
— protected by law —
Sponsor query · matcher fires · 45 sec
MD Anderson posts a Stage II breast cancer trial. Sarah's record matches.
Trial sponsors publish criteria. The matcher engine scans the consenting cohort with k-anonymity floor 10, returns a de-identified cohort count, and surfaces the trial to matching patients. The sponsor never sees identifiers — the patient decides whether to step forward.
Cohort matching against consenting longitudinal records:
0
de-identified matches · k-anonymity floor 10
Sarah K. Walker matched · trial card pushed to her portal
Trial offer in Sarah's portal · 30 sec
Sarah opens her portal. She accepts.
The trial card lands in Sarah's Trial Matches tab. She sees the criteria match, the IRB ID, the compensation amount, and the consent agreement. She accepts in one click. The settlement event fires.
Stage II Breast Cancer · Adjuvant CDK4/6 Trial
MD Anderson Cancer Center · IRB 2026-MA42
$50,000
sponsor pays · gross
✓ You match all criteriaHouston · 4 visits · 18 monthsPhase III · FDA-registeredYour share: $39,600 NET (80% after fees)
A randomized trial evaluating an adjuvant CDK4/6 inhibitor on top of standard endocrine therapy. Quarterly clinical visits. Imaging covered by sponsor. Compensation paid in 4 milestones via Velo ACH; full breakdown in the next step.
Confidential ledger · 15 sec
Every event is HMAC-signed and written to Azure Confidential Ledger.
Tamper-evident. Independently auditable by HHS OCR or any third-party. Sarah, the sponsor, the buyer, and Moonlitic each can prove the same chain of events down to the millisecond.
Settlement created — F06 Payouts disbursement-engine
payout-id · po_a1b2c3... · gross $50,000.00
12:04:18.681
✓
Ledger seal — HMAC-SHA256 chain
prev-hash · 7c44...88e1 · this-hash · 9d12...4af3
12:04:18.799
The money shot · 60 sec
The 80/20 NET cascade fires. Sarah gets paid.
Buyer paid $50,000 — this is a premium oncology trial (top of the price band; marketplace weighted average is $655/record). Per-transaction platform costs come off GROSS. NET splits 80/20. Sarah's ACH receipt drops in 3 business days.
Sarah's payout — settling now
$0.00
ACH transfer · Velo Payments · KYC verified · 1099-NEC tracked
NET available for splitafter platform-cost line items
99.0%
$49,500.00
→ Sarah (80% of NET)ACH within 3 business days
80%
$39,600.00
→ Moonlitic (20% of NET)platform revenue · Stream 5
20%
$9,900.00
💳
ACH initiated · Velo Payments → Chase ****6411 · 3 business days
Sarah will receive $39,600.00 — net of all platform fees
Now multiply · 30 sec
One Sarah is the example. $12.1B Year 5 total revenue is the math.
Six revenue streams stack independently per CEO 5-year projection. Three are annuity (Council, Tiles, Payments). Three scale with consumer + marketplace adoption. Plus $12.76B+ flowing annually to patients at 1% US-population marketplace penetration — the flywheel.
Plus $12.76B flowing annually to patients via 80/20 cascade at 1% US-pop marketplace penetration — the flywheel that drives consent + referral + organic growth.
Patient share · not Moonlitic revenue · counted separately
Patient trust is built on regulators. We sit on all of them.
Eight federal frameworks. Three state privacy laws wired into the engine. Five industry standards. ~80% NIST 800-53 Moderate. Phase 1 of an independent code-level audit closed. New entrants take years to reach this baseline — and the patient feels every layer of it.
Three product lines. Five revenue streams. One platform.
Moonlitic is a patient-owned health-data exchange, a bi-directional clinical-trials matching platform, and a payments-rail product — built on a shared compliance and consent core. Each line survives standalone; together they compound.
📊 Data Exchange
Patient-owned longitudinal data. 11 buyer types. 7 categories. 80/20 NET split. Velo-rail ACH disbursement.